Sinco Pharma released its 2025 Environmental, Social and Governance (ESG) Report, outlining measurable progress on emissions, waste, employee development and governance.
The company cut Scope 2 carbon emissions—those tied to purchased electricity—to 454.24 tonnes of CO₂-e, down 42 % from 782.45 tonnes a year earlier, helped by energy-efficiency measures in newly commissioned cold-chain facilities. Scope 1 emissions edged up to 82.20 tonnes of CO₂-e, as expanded logistics operations lifted fuel use and refrigerant replenishment. Total electricity consumption rose 23 % to 1.84 million kWh, reflecting the full-year operation of the Chengdu cold-chain warehouse, while water use increased to 8,664 m³ following aseptic simulation trials.
Hazardous waste generation fell 42 % to 6.55 tonnes, and non-hazardous waste rose modestly to 11.47 tonnes. A new Waste Management System stipulates classification, specialist storage and third-party disposal of hazardous materials.
Sinco Pharma set new mid-term climate goals: a 5 % reduction in Scope 1 and Scope 2 emission intensity by 2028 (baseline 2025) and alignment with China’s carbon-peaking target by 2030 and carbon-neutrality goal by 2060.
No material breaches of environmental, employment, health-and-safety, product-quality or data-privacy laws were reported. The company maintained a zero-incident record on work-related fatalities and logged no lost-time injuries during the year.
Headcount fell to 261 from 291, yet training coverage rose to 97.7 % of staff, up 15.6 percentage points year on year, with average training hours of 23.1 per employee. Three additional patents were secured, bringing the total patent portfolio to 20, and subsidiary Chengdu Hengmeisheng maintained its ISO 13485 medical-device quality certification.
Governance measures include a three-tier ESG structure overseen by the board, updated anti-corruption protocols and a confidential whistle-blowing channel. The company reported no corruption, fraud or money-laundering cases.
Supply-chain oversight was strengthened through comprehensive vendor audits and emergency plans for cold-chain logistics. Sinco Pharma also continued its public-health outreach via educational articles and sustained operations of the Sinco Charitable Foundation established in 2017.
Comments